Literature DB >> 26101702

URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin.

Junxia Gu1, Yuting Liang1, Longwei Qiao1, Yaojuan Lu2, Xiaoxia Hu1, Dongwei Luo1, Na Li1, Leilei Zhang1, Yiyang Chen1, Jialu Du1, Qiping Zheng2.   

Abstract

Cervical cancer is a common and devastating female cancer worldwide. The etiology of cervical cancer has been largely attributed to human papillomavirus (HPV) infection and activation of the P13K/AKT/mTOR (mammalian target of rapamycin) pathway. However, the limited HPV-directed therapy, as well as therapeutic approach targeting P13K/AKT/mTOR pathway, has not yet been established or effective. A deeper understanding of cervical carcinogenesis and finding of novel candidate molecules for cervical cancer therapeutics is largely warranted. The unconventional prefoldin RPB5 interactor (URI or URI1), a known transcription factor involving the TOR signaling pathway, has recently been implicated a role in multiple tumorigenesis. We recently reported significant upregulation of URI in precancerous cervical intra-epithelial neoplasia (CIN) and invasive cervical cancer, suggesting its role in cervical carcinogenesis. However, the effect and underlying mechanism of URI in cervical cancer development have never been elucidated. Here, we aimed to investigate the in vitro effect of URI on cervical cancer using two cervical cancer cell lines CaSki and C33A, which are HPV-positive and HPV-negative respectively. We have shown that forced over-expression of URI in C33A and CaSki cells markedly promoted cell growth, while down-regulation of URI mediated by siRNA inhibited cell proliferation. We have found that URI over-expression enhanced resistance of cervical cancer cells to cisplatin. In contrast, knockdown of URI promoted apoptosis by influencing cell response to cisplatin, supporting URI as an oncogenic protein for cervical cancer cells. We have also shown that URI promoted the migration and invasive capacity of cervical cancer cells by up-regulation of Vimentin, a mesenchymal cell migration marker relating to the epithelial-mesenchymal transition (EMT) program. Our data support an important function of URI in the biological behavior of cervical cancer cells and provide novel mechanistic insights into the role of URI in cervical cancer progression and possibly, metastasis.

Entities:  

Keywords:  C33A and CaSki cell lines; URI; cervical cancer invasive capacity; cisplatin; epithelial-mesenchymal transition; vimentin

Year:  2015        PMID: 26101702      PMCID: PMC4473315     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  32 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

3.  Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines.

Authors:  D Wrede; J A Tidy; T Crook; D Lane; K H Vousden
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP.

Authors:  Paolo Mita; Jeffrey N Savas; Nabil Djouder; John R Yates; Susan Ha; Rachel Ruoff; Eric D Schafler; Jerome C Nwachukwu; Naoko Tanese; Nicholas J Cowan; Jiri Zavadil; Michael J Garabedian; Susan K Logan
Journal:  Mol Cell Biol       Date:  2011-07-05       Impact factor: 4.272

Review 6.  Chemotherapy for recurrent cervical carcinoma.

Authors:  David H Moore
Journal:  Curr Opin Oncol       Date:  2006-09       Impact factor: 3.645

7.  Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Authors:  K Vuoriluoto; H Haugen; S Kiviluoto; J-P Mpindi; J Nevo; C Gjerdrum; C Tiron; J B Lorens; J Ivaska
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 8.  Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.

Authors:  Donna Dehn; Kathleen C Torkko; Kenneth R Shroyer
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

Review 9.  Cancer associated human papillomaviruses.

Authors:  Margaret E McLaughlin-Drubin; Jordan Meyers; Karl Munger
Journal:  Curr Opin Virol       Date:  2012-06-02       Impact factor: 7.090

10.  URI is an oncogene amplified in ovarian cancer cells and is required for their survival.

Authors:  Jean-Philippe Theurillat; Stefan Christian Metzler; Nico Henzi; Nabil Djouder; Marianne Helbling; Anna-Kathrin Zimmermann; Francis Jacob; Alex Soltermann; Rosmarie Caduff; Viola Heinzelmann-Schwarz; Holger Moch; Wilhelm Krek
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

View more
  14 in total

1.  Role of RP11-83J16.1, a novel long non-coding RNA, in rheumatoid arthritis.

Authors:  Xuemei Piao; Jieru Zhou; Jiandong Hu
Journal:  Am J Transl Res       Date:  2020-04-15       Impact factor: 4.060

2.  URI prevents potassium dichromate-induced oxidative stress and cell death in gastric cancer cells.

Authors:  Dongwei Luo; Zhonghai Xu; Xiaoxia Hu; Fei Zhang; Huiqin Bian; Na Li; Qian Wang; Yaojuan Lu; Qiping Zheng; Junxia Gu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  The chemokine receptor CCR1 is identified in mast cell-derived exosomes.

Authors:  Yuting Liang; Longwei Qiao; Xia Peng; Zelin Cui; Yue Yin; Huanjin Liao; Min Jiang; Li Li
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

Review 4.  Prefoldin, a jellyfish-like molecular chaperone: functional cooperation with a group II chaperonin and beyond.

Authors:  Muhamad Sahlan; Tamotsu Zako; Masafumi Yohda
Journal:  Biophys Rev       Date:  2018-02-09

5.  URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro.

Authors:  Xiaoxia Hu; Fei Zhang; Dongwei Luo; Na Li; Qian Wang; Zhonghai Xu; Huiqin Bian; Yuting Liang; Yaojuan Lu; Qiping Zheng; Junxia Gu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

6.  URI promotes the migration and invasion of human cervical cancer cells potentially via upregulation of vimentin expression.

Authors:  Zhonghai Xu; Huiqin Bian; Fei Zhang; Rui Mi; Qian Wang; Yaojuan Lu; Qiping Zheng; Junxia Gu
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

7.  Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1.

Authors:  Kamil Andrzej Lipinski; Christian Britschgi; Karen Schrader; Yann Christinat; Lukas Frischknecht; Wilhelm Krek
Journal:  Oncotarget       Date:  2016-05-17

8.  Expression Profiling and Functional Analysis of Candidate Col10a1 Regulators Identified by the TRAP Program.

Authors:  Huiqin Bian; Ting Zhu; Yuting Liang; Ruoxuan Hei; Xiaojing Zhang; Xiaochen Li; Jinnan Chen; Yaojuan Lu; Junxia Gu; Longwei Qiao; Qiping Zheng
Journal:  Front Genet       Date:  2021-07-02       Impact factor: 4.599

9.  PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.

Authors:  Xiang-Rong Shu; Jing Wu; He Sun; Li-Qun Chi; Jin-Huan Wang
Journal:  Diagn Pathol       Date:  2015-09-28       Impact factor: 2.644

10.  miR-488 inhibits cell growth and metastasis in renal cell carcinoma by targeting HMGN5.

Authors:  Xin Wei; Lili Yu; Xiangbo Kong
Journal:  Onco Targets Ther       Date:  2018-04-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.